SillaJen, Inc. (SillaJen)

Oncology Corporate Profile

HQ Location

63 Beon-gil Geumjeong-gu, Busan 609-735 Korea
Busan, Korea 609-735

Company Description

SillaJen, Inc. is a privately-held biotechnology company focusing on engineering and developing best-in-class oncolytic immunotherapeutics. SillaJen has Korean offices in Busan (R&D), at Pusan National University (PNU), and in Seoul (finance, management & legal). SillaJen also has Clinical R&D, regulatory affairs and CMC capabilities in San Francisco, California, one of the world's leading biotechnology centers and the 'birthplace'? of the biotech industry. SillaJen products are engineered from vaccinia which has unique attributes as an oncolytic immunotherapy.

Website: http://www.sillajen.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
JX-594oncolytic poxvirusColorectal cancerIITransgene
JX-594oncolytic poxvirusHepatocellular carcinoma (HCC)IITransgene
JX-594oncolytic poxvirusRenal cell carcinoma (RCC)II
Pexa-Vec (+ REGN2810)oncolytic poxvirusRenal cell carcinoma (RCC)IRegeneron
JX-594oncolytic poxvirusVarious cancer typesITransgene
JX-929oncolytic poxvirusVarious cancer typesI

View additional information on product candidates here »

Source: http://www.SillaJen.com

Recent News Headlines

SillaJen Biotherapeutics Completes Name Change

6/23/2014 08:01 am

(CenterWatch) June 20, 2014 - SillaJen, a privately held biotherapeutics company focused on development of targeted oncolytic immunotherapy products for cancer, has completed its name change to SillaJen Biotherapeutics following its acquisition of Jennerex Biotherapeutics.

Global Partners SillaJen, Transgene and Lee’s Pharmaceutical Confirm Clinical Development Plan for Pexa-Vec

3/26/2014 11:57 am

(Yahoo! Finance) Mar 26, 2014 - Transgene SA, Lee’s Pharmaceutical and SillaJen today unveiled their late-stage clinical development plan for Pexa-Vec (JX-594/TG6006) oncolytic immunotherapy.

Transgene CEO Sees No Change to Pexa-Vec Plan After Deal

11/26/2013 11:02 am

(Bloomberg) Nov 26, 2013 - Transgene SA said it expects the development of the experimental Pexa-Vec cancer treatment to proceed according to plan after the purchase of U.S. partner Jennerex BioTherapeutics Inc.

Jennerex Announces That Its Phase 2 Study of Pexa-Vec in Second-Line Advanced Liver Cancer Did Not Meet Its Primary Endpoint

9/4/2013 11:01 am

(Yahoo! Finance) Sep 3, 2013 - Jennerex Biotherapeutics, Inc. today announced that TRAVERSE, a randomized Phase 2b study of Pexa-Vec in second-line, advanced liver cancer patients had reached the pre-specified number of events for analysis.

Jennerex Granted FDA Orphan Drug Designation for Pexa-Vec in Hepatocellular Carcinoma (HCC)

5/9/2013 12:01 pm

(Yahoo! Finance) May 8, 2013 - Top-line data from TRAVERSE, phase 2b Pexa-Vec trial in Hepatocellular Carcinoma, expected at year end.

Aveo's Kidney Cancer Drug Won't Get FDA Panel OK

4/25/2013 11:04 am

(The Street) Apr 25, 2013 - Next week is crucial for Aveo Oncology. On Tuesday, the FDA will post to its web site the agency's clinical review of Aveo's experimental kidney cancer drug tivozanib.

Jennerex Presents Positive Clinical Data from Phase 2 Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients

9/17/2012 11:03 am

(Boston.com) Sept 17, 2012 - Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic immunotherapies, presented Phase 2 clinical data of JX-594 delivered first intravenously and subsequently through intra-tumoral route demonstrating safety as well as disease control and tumor responses in patients with hepatocellular carcinoma (liver cancer, HCC).

Accretive Health and Cancer Clinics of Excellence to Develop Innovative Program Providing Oncology Care Management

8/30/2012 11:04 am

(Yahoo! Finance) Aug 29, 2012 - Accretive Health, Inc., a healthcare technology and services company, and Cancer Clinics of Excellence (CCE), a national network of practice-owned, physician-driven community-based oncology practices, announced today that they have partnered to develop a novel, end-to-end oncology care management offering designed to enable healthcare providers to improve the efficacy and quality of cancer care while simultaneously improving the affordability of the healthcare system.

Jennerex Announces First Patient Treated in Phase 2 Clinical Trial of Intravenous Delivery JX-594 In Patients with Advanced Liver Cancer

7/25/2012 12:00 pm

(Yahoo! Finance) July 25, 2012 - Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic immunotherapies, today announced that the first patient has been treated in a Phase 2 clinical trial of intravenous treatment with JX-594 for patients with advanced hepatocellular carcinoma (HCC), or liver cancer, who have not received treatment with sorafenib—the current standard of care for this patient population.

Jennerex Presents JX-594 Clinical Data at 2012 American Society of Clinical Oncology Annual Meeting

6/4/2012 05:05 pm

(Yahoo! Finance) June 4, 2012 - Jennerex highlights phase 2b liver cancer trial as well as programs in colorectal cancer and multi-dose IV administration.

Pre-Op Treatments Boost Survival for Esophageal Cancer Patients: Study

5/31/2012 07:05 am

(U.S. News & World Report/HealthDay News) May 30, 2012 - Patients with esophageal cancer who receive chemotherapy and radiation before surgery have better outcomes, Dutch researchers report.

Women Not Following Through with Recommended Breast Screening MRI

2/1/2012 11:05 am

(Colorado Cancer Center blog) Jan 31, 2012 - A study of 64,659 women, recently published in the journal Academic Radiology, found that while 1,246 of these women were at high enough breast cancer risk to recommend additional screening with MRI, only 173 of these women returned to the clinic within a year for the additional screening.

Celsion Announces Drug Safety Monitoring Board Recommends Advancing DIGNITY Study of ThermoDox(R) in Recurrent Chest Wall Breast Cancer Into Phase II

6/8/2011 12:00 pm

(MSNBC) June 8, 2011 - Celsion Corporation today announced that after reviewing safety data from the Company's recently completed Phase I portion of the DIGNITY Phase I/II study of ThermoDox® and hyperthermia in recurrent chest wall (RCW) breast cancer (the DIGNITY Study), an independent Drug Safety Monitoring Board (DSMB) has recommended advancing from Phase I to Phase II at 50 mg/m2 of ThermoDox®.

FDA, FTC Seek To End Sales Of Unproven STD-Treatment Drugs

5/4/2011 12:04 pm

(Wall Street Journal) May 3, 2011 - Halting the sale of products that make unproven claims of treating or preventing sexually transmitted diseases is the goal of a joint effort by the U.S. Food and Drug Administration and Federal Trade Commission.

Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Abbott

3/22/2011 12:05 pm

(Seattle Genetics) Mar 22, 2011 - Seattle Genetics, Inc. today announced that it has entered into a collaboration agreement with Abbott under which Abbott will pay an upfront fee of $8 million for rights to utilize Seattle Genetics' antibody-drug conjugate (ADC) technology with antibodies to a single oncology target.